POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
June 26 2023 - 7:30AM
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or
“POINT”), a company accelerating the discovery, development, and
global access to life-changing radiopharmaceuticals, today
announced the publication of preclinical data from their
pan-cancer, fibroblast activation protein-α (FAP)-targeted program,
PNT2004, at the 2023 Annual Meeting of the Society of Nuclear
Medicine & Molecular Imaging (SNMMI), taking place June 24-27,
2023, in Chicago, IL.
PNT6555, the lead candidate in the PNT2004
program, led to complete and durable tumor regression and improved
survival in HEK-mFAP tumor-bearing mice when chelated to any one of
the three radioisotopes studied: lutetium-177 (177Lu), actinium-225
(225Ac), and terbium-161 (161Tb). Additionally, 177Lu-PNT6555 in
combination with anti-PD-1 checkpoint blockade was assessed in the
aggressive, immunocompetent CT26-mFAP mouse model and demonstrated
a significant survival benefit compared to either treatment
alone.
“By continuing to develop expertise in more
isotopes, POINT is better positioned to create optimized
next-generation radioligands, which match a ligand’s properties
with the most appropriate isotope,” said Joe McCann, Ph.D., Chief
Executive Officer of POINT Biopharma. “The expertise to discover
and develop new radioligands and advance them into clinical trials
has been built into POINT. We look to fill our toolbox of isotopes
as full as we can, evaluate them in discovery and development, and
aim to bring forward candidates we believe could generate
compelling patient benefit.”
Presentation details are as follows:
Title: Preclinical application
of novel isotopes and combination therapy with the FAP-targeted
ligand PNT6555Abstract ID: 180Session
Name: Imaging and Therapy in Preclinical Oncology Models -
Session 2Session Date: Monday, June 26th
Session Time: 10:00 AM - 11:15 AM
CTPresentation Time: 10:45 AM – 10:55 AM CT
Following the presentation of these data the
poster will be made available on POINT’s Investor Relations
website, https://pointbiopharma.com/investors.
About POINT
BiopharmaPOINT Biopharma Global Inc. is a globally focused
radiopharmaceutical company building a platform for the clinical
development and commercialization of radioligands that fight
cancer. POINT aims to transform precision oncology by combining a
portfolio of targeted radioligand assets, a seasoned management
team, an industry-leading pipeline, in-house manufacturing
capabilities, and secured supply for medical isotopes including
actinium-225 and lutetium-177. POINT’s active clinical trials
include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program
targeting fibroblast activation protein-α (FAP-α), and SPLASH, the
phase 3 trial for PNT2002 for people with metastatic castration
resistant prostate cancer (mCRPC) after second-line hormonal
treatment. Learn more about POINT Biopharma Global Inc.
at https://www.pointbiopharma.com/.Forward Looking
StatementsThis press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995. In some
cases, you can identify forward-looking statements by the following
words: “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement
contained in this press release, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the benefits of the recently completed business combination, as
well as statements about the potential attributes and benefits of
POINT’s product candidates and the format and timing of POINT’s
product development activities and clinical trials. We cannot
assure you that the forward-looking statements in this press
release will prove to be accurate. These forward-looking statements
are subject to a number of significant risks and uncertainties that
could cause actual results to differ materially from expected
results, including, among others, our ability to grow and manage
our growth profitably and retain our key employees, the impact of
COVID-19 on our business, the success, cost and timing of our
product development activities and clinical trials, our ability to
obtain and maintain regulatory approval for our product candidates,
our ability to obtain funding for our operations, our the ability
to maintain the listing of our common stock on the NASDAQ, changes
in applicable laws or regulations, the possibility that POINT may
be adversely affected by other economic, business, and/or
competitive factors, and other risks and uncertainties, including
those described in our Annual Report on Form 10-K filed with the
SEC on March 27, 2023. Many of these factors are outside of POINT’s
control and are difficult to predict. Furthermore, if the
forward-looking statements prove to be inaccurate, the inaccuracy
may be material. In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by us or any other person that we
will achieve our objectives and plans in any specified time frame,
or at all. The forward-looking statements in this press release
represent our views as of the date of this press release. We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we have no
current intention of doing so except to the extent required by
applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Investor
Relations Contact:Daniel PearlsteinDirector,
Strategyinvestors@pointbiopharma.com
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
From Sep 2023 to Sep 2024